EGFR and lung cancer: Using RNAi, the authors showed that Fas could render EGFR mutant lung cancer cells independent of the mutant EGFR and thereby resistant to erlotinib by acting upstream of persistent NFkB signaling and an unidentified MEK-independent pathway20.